Detailed company information
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Last Updated: Sep 2026
Earnings Transcript for 2025 - Q4Released: Feb 26, 2026
Earnings Transcript for 2025 - Q3Released: Nov 04, 2025
Earnings Transcript for 2025 - Q2Released: Jul 31, 2025
Earnings Transcript for 2025 - Q1Released: May 12, 2025
Earnings Transcript for 2024 - Q4Released: Feb 27, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 01, 2024
Earnings Transcript for 2024 - Q1Released: May 02, 2024
Earnings Transcript for 2023 - Q4Released: Feb 15, 2024
Earnings Transcript for 2023 - Q3Released: Nov 02, 2023
Earnings Transcript for 2023 - Q2Released: Aug 03, 2023
Earnings Transcript for 2023 - Q1Released: May 04, 2023
Earnings Transcript for 2022 - Q4Released: Feb 28, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 04, 2022
Earnings Transcript for 2022 - Q1Released: May 10, 2022
Earnings Transcript for 2021 - Q4Released: Feb 28, 2022
Earnings Transcript for 2021 - Q3Released: Nov 03, 2021
Earnings Transcript for 2021 - Q2Released: Aug 05, 2021
Earnings Transcript for 2021 - Q1Released: May 07, 2021
Earnings Transcript for 2020 - Q4Released: Feb 24, 2021
Earnings Transcript for 2020 - Q3Released: Nov 10, 2020
Earnings Transcript for 2020 - Q2Released: Aug 12, 2020
Earnings Transcript for 2020 - Q1Released: May 15, 2020
Aurinia Pharmaceuticals’ 2026 sales guidance for LUPKYNIS factors in competitive pressures from Gazyva qualitatively, without providing explicit dollar or percentage impact figures. The guidance anticipates market growth amid competition, emphasizing product differentiation and a growing lupus nephritis market.
Read post
Dafinchi
